Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Want a daily digest of the top Nashville news?
Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.
Want a daily digest of the top Columbus news?
Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.
Want a daily digest of the top Dallas news?
Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
Small bottles filled with a sterile cancer drug. Photo: Hendrik Schmidt/Getty Images
Pharmaceutical investment in cancer treatments has risen drastically over the past decade, as has spending on cancer drugs, but the results have been comparatively small, UC Hastings law professor Robin Feldman argues in a WashPost op-ed.
Why it matters: Every dollar invested in cancer is a dollar that isn't invested elsewhere — for example, in antibiotics.
- "The greatest risk is not only that our moonshot may fail, but that the nation’s other public health needs will be left in the dust," Feldman writes.
- U.S. law — including law designed to increase investment in rare diseases — incentivizes companies to invest in cancer, she adds.
- "By classifying so many cancers as rare diseases afflicting under 200,000 people each, this regulatory setup has unleashed a veritable tidal wave of oncology drugs," she writes.
By the numbers: Since 2013, cancer drug spending as a proportion of all U.S. drug spending has increased by nearly 60%, but the overall death rate from cancer has decreased by only 5% since 1950.
- Cancer drugs approved between 2003 and 2013 increased survival by an average of 3.4 months.
Go deeper: Pharma goes all in on cancer treatments